Law360 (April 5, 2021, 8:32 PM EDT) — Inscripta Inc., a Colorado-based gene editing technology company, secured $150 million in a financing round led by Fidelity Management & Research Company LLC with advice from T. Rowe Price Associates Inc., according to an announcement Monday.
The Series E round featured new investors D1 Capital Partners and Durable Capital Partners LP and returning investors including Foresite Capital; Counterpoint Global, which is part of Morgan Stanley; and JS Capital LLC.
Representatives for Fidelity and T. Rowe Price did not immediately respond to requests for comment Monday. Other investors in the round could not immediately be reached for comment.
The close of Inscripta’s…
Stay ahead of the curve
In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.
Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
Create custom alerts for specific article and case topics and so much more!